Targeting EZH2 to help brain tumors mature and become less harmful
Inducing Neural Maturation in Medulloblastoma by Targeting EZH2
This study is looking at how to help children with medulloblastoma, a common brain tumor, by figuring out how to make these tumors less aggressive and finding better, safer treatments to improve their health and future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10906296 on NIH RePORTER |
What this research studies
This research focuses on medulloblastoma, the most common brain tumor in children, which is often difficult to treat and can lead to severe long-term health issues. The study aims to understand how certain brain tumors can mature into less aggressive forms and to identify ways to induce this maturation in patients. By exploring the genetic and epigenetic factors involved, the researchers hope to develop new therapies that are more effective and less toxic than current treatments. This could potentially improve outcomes for children diagnosed with this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma or those who have survived this condition.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with medulloblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for children with medulloblastoma, reducing long-term health complications.
How similar studies have performed: Other research has shown promise in targeting epigenetic factors in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Snuderl, Matija — New York University School of Medicine
- Study coordinator: Snuderl, Matija
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.